|
Referencias
1. Alberts M. tPA in acute ischemic stroke. United States experience and issues for the future. Neurology 1988; 51(suppl 3): 53-5S.
2. Wardlaw JM, Yamaguchi T, del Zoppo G. Thrombolytic therapy versus control in acute ischaemic stroke. In: Cochrane Collaboration,ed. Cochrane Library. Issue 4. Oxford: Update Software, 1999.
3. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ 1997; 314: 1151-1159.
4. Sandercock P, Gubitz G, Counsell C. Antiplatelet therapy for acute ischaemic stroke. In: Cochrane Collaboration,ed. Cochrane Library. Issue 1. Oxford: Update Software, 2000.
5. Murray DJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-1276
6. Sandercock P. Preventing recurrent stroke and other serious vascular events. In: Stroke. A practical guide to management. 2 ed. Oxford: Blackwell Science Management (in press).
7. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
8. Peto R. Smoking and death: the past 40 years and the next 40. BMJ 1994; 309: 937-939
9. Hillbom M, Juvela S, Numminen H. Alcohol intake and risk of stroke. J Cardiovasc Risk 1999; 6: 223-228
10. Sigal R. Cardiovascular disease in diabetes mellitus. In: Godlee F, Goldmann D, Donald A, Barton S, eds. Clinical Evidence, issue 2. London: BMJ Publishing Group, 1999:32-44.
11. Brand MB, Mulrow CD, Chiquette E, Angel L, Cornell J, Summerbell C, et al. Dieting to reduce body weight for controlling hypertension in adults. Cochrane Collaboration. In: Cochrane Library, 1999, Issue 3. Oxford: Update Software, 1999.
12. Wannamethee SG, Shaper A. Physical activity and the prevention of stroke. J Cardiovasc Risk 1999; 6: 213-216
13. Search strategy of the Cochrane Stroke Group. In: Cochrane Collaboration. In: Cochrane Library. Issue 1. Oxford: Update Software, 2000.
14. Godlee F, Goldmann D, Donald A, Barton S, eds. Clinical Evidence, issue 2. London: BMJ Publishing Group, 1999.
15. MacMahon S, Rodgers A. The epidemiological association between blood pressure and stroke: implications for primary and secondary prevention. Hypertens Res 1994; 17(suppl I): 23-32S.
16. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, et al. Prevention of a first stroke. A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999; 281: 1112-1120
17. The INDANA (Individual Data Analysis of Antihypertensive intervention trials) Project Collaborators. Effect of antihypertensive treatment in patients having already suffered a stroke. Stroke 1997; 28: 2557-2562
18. Mulrow C, Jackson R. Treating primary hypertension. In: Godlee F, Goldmann D, Donald A, Barton S, eds. Clinical Evidence, issue 2. London: BMJ Publishing Group, 1999:524-531.
19. Hansson L, Lindholm L, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish trial in old patients with hypertension-2 study. Lancet 1999; 354: 1751-1756
20. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design of PROGRESS. J Hypertens 1996; 14(suppl 2): 41-6S.
21. Pekkanen J, Linn S, Heiss G, Suchindron CM, Leon A, Ruskind BM, et al. Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-1707
22. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997; 278: 313-321.
23. Collins R, Peto R. MRC/BHF heart protection study. Stroke 1999; 30: 1304. (Abstract.)
24. Goldstein L, for the SPARCL Investigators. Stroke prevention by aggressive reduction in cholesterol levels the SPARCL study [abstract]. 25th International Stroke Conference, New Orleans, Feb 2000.
25. Cholesterol Treatment Trialists' Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol 1995; 75: 1130-1134
26. The Heart Outcomes Prevention Evaluation [HOPE] Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153
27. Taylor DW, Barnett HJM, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet 1999; 353: 2179-2184
28. Hankey GJ, Sudlow C, Dunbabin D. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for prevention of stroke and other serious vascular events in high vascular risk patients. In: Cochrane Collaboration,ed. Cochrane Library. Issue 4. Oxford: Update Software, 1999.
29. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European secondary prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13
30. Wilterdink JL, Easton JD. Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 1999; 56: 1087-1092
31. De Schryver E, for the ESPRIT Study Group. ESPRIT: mild anticoagulation, acetylsalicylic acid plus dipyridamole or acetylsalicylic acid alone after cerebral ischaemia of arterial origin [abstract]. Cerebrovasc Dis 1998; 8(suppl 4): 83.
32. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501
33. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997; 28: 1015-1021
34. Chen Z, Sandercock P, Counsell C, Dan HC, Collins R, Liu L, et al. Indications for early aspirin use in acute ischaemic stroke: a combined analysis of 40,000 randomised patients from the Chinese acute stroke trials and the international stroke trial. Stroke 2000; 31: 1240-1249
35. Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack. In: Cochrane Collaboration,ed. Cochrane Library. Issue 3. Oxford: Update Software, 1999.
36. The Stroke Prevention in Reversible Ischaemia Trial (SPIRIT) Study Group. A randomised trial of anticoagulant versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-865
37. Mohr J, for the WARSS Group. Design considerations for the warfarin-antiplatelet recurrent stroke study. Cerebrovasc Dis 1995; 5: 156-157.
38. Cina C, Clase C, Haynes R. Carotid endarterectomy for symptomatic stenosis. In: Cochrane Collaboration,ed. Cochrane Library. Issue 3. Oxford: Update Software, 1999.
39. Brown M, for the CAVATAS Investigators. Results of the carotid and vertebral artery transluminal angioplasty study (CAVATAS) [abstract]. Cerebrovasc Dis 1999; 9(suppl 1): 21
40. Al-Mubarak N, Roubin G, Hobson R, Ferguson R, Brott T, Moore W. Credentialling of stent operators for the carotid revascularization endarterectomy vs stenting trial (CREST) [abstract]. Stroke 2000; 31: 292.
41. Gough M, for the GALA Investigators. General versus local anaesthesia for carotid endarterectomy (GALA).
42. Benavente O, Moher D, Pham B. Carotid endarterectomy for asymptomatic carotid stenosis: a meta-analysis. BMJ 1998; 317: 1477-1480
43. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, cost, and effects on individuals and populations. Lancet 1999; 34: 1457-1463
|
Procesando
Inicio
